Advertisement
The Sino-German Workshop on Sleep Research was organized jointly byHeilongjiang University of Chinese Medicine and MPI of Psychiatry, Munich,Center of Mental Health. The workshop was sponsored by the Sino-German Centerfor Research Promotion and co-sponsored by Renhuang Pharmaceuticals, Inc.Professor Tingli Li of Heilongjiang University of Chinese Medicine and Mr.Shaoming Li, President and CEO of Renhuang Pharmaceuticals represented the PRCas co-chairs of the workshop.
Advertisement
At the workshop, over 50 scientists from China, Germany, the U.S., Holland,Austria, Russia, Japan and other countries presented their research findingson a wide variety of topics, including sleep apnea, anxiety induced sleepdisorders, insomnia, and shared statistics regarding Chinese treatments forsleep disorders.
Renhuang presented the study results on its leading branded drug,Acanthopanax (Siberian Ginseng), which treats sleep disorders and depressionby reducing tension and putting individuals in a more relaxed state. SinceAcanthopanax was the only drug with a significant amount of researchsupporting its use in the treatment of sleep disorders at the workshop, itgarnered a great deal of attention among the workshop attendees.
"By co-sponsoring the Sino-German Workshop on Sleep Disorders, wecontinued our strategy of increasing our presence at scientific workshops andincreasing our communications and exchanging study results with well knownresearchers around the world. We plan to reach out to more professionalsregarding the use of Acanthopanax in the treatment of sleep disorders, whichwill further expand our global reach," said Mr. Shao-ming Li, Chairman and CEOof Renhaung Pharmaceuticals, Inc.
About Renhuang Pharmaceuticals, Inc.
Founded in 1996, Renhuang Pharmaceuticals, Inc, produces western,traditional Chinese medicines (TCM), and branded pharmaceuticals, using itsGMP-certified facilities in China. The Company's GMP-certified manufacturingfacilities, containing cutting-edge technologies and advance equipment, arecapable of producing as many as 200 types of pharmaceuticals. Additionally,Renhuang distributes raw materials and finished pharmaceutical products usingits extensive distribution channels and third party distributors throughoutChina. The Company's distribution network includes over 3,000 salesrepresentatives in 70 sales centers across 24 districts, covering over 50% ofthe greater China. The Company also exports its products to Russia andSoutheast Asia. For more information, visit http://www.renhuang.com .
Safe Harbor Statement
Certain of the statements made in the press release constituteforward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. These statements can be identified by the useof forward-looking terminology such as "believe," "expect," "may," "will,""should," "project," "plan," "seek," "intend," or "anticipate" or the negativethereof or comparable terminology. Such statements typically involve risks anduncertainties and may include financial projections or information regardingour future plans, objectives or performance. Actual results could differmaterially from the expectations reflected in such forward-looking statementsas a result of a variety of factors, including the risks associated with theeffect of changing economic conditions in The People's Republic of China,variations in cash flow, reliance on collaborative retail partners and on newproduct development, variations in new product development, risks associatedwith rapid technological change, and the p
